Evidence map›Paper›PMID 42905320›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026

Increased Expression of Desmin and Vimentin Impairs Mitochondrial Function and Reduces Contractility via G0S2 in Bladder Smooth Muscle.

Elham Javed, Chellappagounder Thangavel, Karthik Thangavel, Joseph Hypolite, Isabelle Gamache, Yilin Wang, Sankar Addya, Darin Mak, Furqan Syed, Jyotsna Mishra and 12 more

Abstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Elham JavedDepartment of Medicine, Center for Translational Medicine, Philadelphia, Pennsylvania, USA.
Chellappagounder ThangavelDepartment of Medicine, Center for Translational Medicine, Philadelphia, Pennsylvania, USA.
Karthik ThangavelDepartment of Pharmaceutical Science, Jefferson College of Pharmacy, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Joseph HypoliteDepartment of Medicine, Center for Translational Medicine, Philadelphia, Pennsylvania, USA.
Isabelle GamacheDepartment of Biochemistry, Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, Quebec, Canada.
Yilin WangDepartment of Biochemistry, Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, Quebec, Canada.
Sankar AddyaCancer Genomics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Darin MakDepartment of Pharmacology, Rutgers Institute for Translational Medicine and Science, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
Furqan SyedDepartment of Pharmacology, Rutgers Institute for Translational Medicine and Science, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
Jyotsna MishraDepartment of Medicine, Center for Translational Medicine, Philadelphia, Pennsylvania, USA.
Vilas DesaiDepartment of Pharmaceutical Science, Jefferson College of Pharmacy, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Pragnya DasCooper University Hospital, Camden, New Jersey, USA.
Dominic R VillalbaDepartment of Medicine, Center for Translational Medicine, Philadelphia, Pennsylvania, USA.
Alok BhushanDepartment of Pharmaceutical Science, Jefferson College of Pharmacy, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Shey-Shing SheuDepartment of Medicine, Center for Translational Medicine, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0003-3838-3601
Sunday A ShoyeleDepartment of Pharmaceutical Science, Jefferson College of Pharmacy, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Erin L SeifertDepartment of Pathology and Genomic Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-8416-5763
Jose G TeodoroDepartment of Biochemistry, Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, Quebec, Canada.
Steven S AnDepartment of Pharmacology, Rutgers Institute for Translational Medicine and Science, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
Raymond B PennDepartment of Medicine, Center for Translational Medicine, Philadelphia, Pennsylvania, USA.
Deepak A DeshpandeDepartment of Medicine, Center for Translational Medicine, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-6187-5332
Ettickan BoopathiDepartment of Medicine, Center for Translational Medicine, Philadelphia, Pennsylvania, USA.

Funding

Mechanisms of contractile dysfunction in the obstructed bladder: Role of desmin and vimentinR01DK129462 · NIDDK · THOMAS JEFFERSON UNIVERSITY · PI ETTICKAN, BOOPATHI · 2022 to 2025
$1.7M
HHS | NIH | NIDDK | Division of Diabetes, Endocrinology, and Metabolic Diseases (DEM) R01DK129462
6 · The paper itself

Abstract

Bladder outlet obstruction caused by benign prostatic hyperplasia in humans, as well as partial bladder outlet obstruction in animal models, is linked to reduced contractility and impaired mitochondrial function in bladder smooth muscle (BSM). However, the mechanisms underlying changes in BSM contractility and mitochondrial function are still largely unknown. Our previous study showed that increased expression of intermediate filament proteins desmin and vimentin weakens BSM contractility. In this study, we hypothesize that BSM contractile dysfunction, driven by elevated levels of desmin and vimentin, is associated with impaired mitochondrial function. Human BSM cells and murine BSM tissue with elevated levels of desmin and vimentin produce less force than control BSM. Notably, increased expression of desmin and vimentin in human BSM cells reduces mitochondrial elongation and branching, with associated decreases in the fusion proteins MFN1 and MFN2, oxygen consumption rate, and ATP levels, and an increase in mitochondrial reactive oxygen species. Microarray analysis revealed significant induction of G0/G1 switch gene 2 (G0S2) mRNA expression in desmin- and vimentin-overexpressing human BSM cells. G0S2 protein interacts with mitochondrial channel protein VDAC in desmin- and vimentin-overexpressing human BSM cells. Silencing G0S2 expression restored BSM contraction, MLC20 phosphorylation, and ATP levels, whereas reducing the mitochondrial ROS and phospho-JNK levels in human BSM cells and murine BSM tissue overexpressing desmin and vimentin. Overall, these findings show that G0S2 plays a critical role in desmin- or vimentin-mediated attenuation of BSM contraction and mitochondrial dysfunction.

Indexed as

DesminMitochondriaMuscle ContractionMuscle, SmoothUrinary BladderVimentinAnimalsHumansMaleMiceReactive Oxygen SpeciesDesminReactive Oxygen SpeciesVimentinbladder smooth musclecontractiondesminG0S2mitochondriaphospho JNKphospho MLC20vimentin

Identifiers

PMID42905320
PMCPMC13686112

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.